Scimed Life Sciences

In 1992, as Singapore was cementing its status as a global hub, SciMed (Asia) Pte Ltd was founded. The company's playbook was clear: act as a key distributor of scientific and medical products for the burgeoning life sciences and healthcare markets across the Asia-Pacific region. From its Singapore headquarters, SciMed built an extensive distribution network, becoming the go-to partner for international brands looking to expand into areas like Southeast Asia and India. From the very beginning, a pivotal relationship was formed with the Japanese conglomerate PHC Group. For decades, this partnership was a classic distribution deal, with SciMed providing the on-the-ground expertise and sales channels for PHC Group's life science equipment. This symbiotic relationship allowed both companies to thrive as the demand for biopharmaceuticals and advanced medical research grew in the region. The dynamic of this long-standing partnership began to shift significantly. In July 2020, PHC Holdings decided to deepen its investment, increasing its stake from a minority holding to a controlling 70% share. This move transformed SciMed into a consolidated subsidiary, integrating it more closely into PHC Group's global strategy. It was a clear signal that SciMed's role was evolving from a partner to a core component of PHC's expansion plans. The final chapter of its independent story was written in June 2023. PHC Holdings acquired the remaining 30% of SciMed, making it a wholly-owned subsidiary. Under the leadership of Managing Director Lilian Gan, the acquisition marked the culmination of a thirty-year journey, moving from a regional distributor to a fully integrated part of a global healthcare leader, poised to accelerate growth in advanced treatments like cell and gene therapies.